Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 45Neuroblastoma 16Glioma 16Brain Neoplasms 14Astrocytoma 10Neoplasms 8Rhabdomyosarcoma 7Sarcoma, Ewing 6Recurrence 5Oligodendroglioma 5Medulloblastoma 5Sarcoma 4Osteosarcoma 4Melanoma 4Small Cell Lung Carcinoma 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Lymphoma 3Gliosarcoma 3Diffuse Intrinsic Pontine Glioma 3Wilms Tumor 2Rhabdoid Tumor 2Pyloric Stenosis, Hypertrophic 2Ovarian Neoplasms 2Neoplasm Metastasis 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2

Interventions

Radiosurgery 3pembrolizumab 1olutasidenib 1Temozolomide 1Restraint, Physical 1Elasticity Imaging Techniques 1Clinical Laboratory Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Spinal Cord Neoplasms × Temozolomide × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡